Kyverna Therapeutics (KYTX) Net Income towards Common Stockholders (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Net Income towards Common Stockholders of -$74.2 million for Q1 2026, down 81.45% on a QoQ basis from -$40.9 million in Q4 2025, and down 62.83% year-over-year from -$199.5 million in Q1 2025.
Kyverna Therapeutics (KYTX) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$74.2 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 62.83% year-over-year to -$74.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$212.1 million (down 24.3% YoY) and the FY2025 annual result came in at -$204.6 million, down 56.97% from the prior year.
- Net Income towards Common Stockholders was -$74.2 million for Q1 2026 at Kyverna Therapeutics, down from -$40.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$11.7 million in Q1 2023 and bottomed at -$74.2 million in Q1 2026.
- A 4-year average of -$36.3 million and a median of -$40.9 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders tumbled 203.32% — and 2025, when it fell 1.11%.
- Kyverna Therapeutics' Net Income towards Common Stockholders stood at -$19.0 million in 2023, then plunged by 112.69% to -$40.4 million in 2024, then fell by 1.11% to -$40.9 million in 2025, then slumped by 81.45% to -$74.2 million in 2026.
- Business Quant data shows KYTX's Net Income towards Common Stockholders at -$74.2 million in Q1 2026, -$40.9 million in Q4 2025, and -$52.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Kyverna Therapeutics | 447.52 Mn | 447.52 Mn | - | -74.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.16 Mn |
| Dec 31, 2025 | -40.87 Mn |
| Sep 30, 2025 | -52.85 Mn |
| Jun 30, 2025 | -44.21 Mn |
| Mar 31, 2025 | -45.55 Mn |
| Dec 31, 2024 | -40.42 Mn |
| Sep 30, 2024 | -43.29 Mn |
| Jun 30, 2024 | -41.37 Mn |
| Mar 31, 2024 | -28.42 Mn |
| Dec 31, 2023 | -19.01 Mn |
| Sep 30, 2023 | -16.00 Mn |
| Jun 30, 2023 | -13.64 Mn |
| Mar 31, 2023 | -11.66 Mn |